Silvana Spadafora

2.4k total citations
22 papers, 661 citations indexed

About

Silvana Spadafora is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Silvana Spadafora has authored 22 papers receiving a total of 661 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Molecular Biology. Recurrent topics in Silvana Spadafora's work include Bone health and treatments (4 papers), Economic and Financial Impacts of Cancer (4 papers) and Advances in Oncology and Radiotherapy (4 papers). Silvana Spadafora is often cited by papers focused on Bone health and treatments (4 papers), Economic and Financial Impacts of Cancer (4 papers) and Advances in Oncology and Radiotherapy (4 papers). Silvana Spadafora collaborates with scholars based in Canada, United States and Austria. Silvana Spadafora's co-authors include Rowan T. Chlebowski, Devchand Paul, Michelle Fan, Georgiana K. Ellis, Henry G. Bone, J. W. G. Smith, Susie Jun, Dennis Kim, Marc Peeters and Yves Humblet and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Silvana Spadafora

18 papers receiving 643 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Silvana Spadafora Canada 8 531 235 165 130 123 22 661
Joseph D. Kohles United States 11 244 0.5× 121 0.5× 86 0.5× 66 0.5× 46 0.4× 25 416
J. Brandman United States 15 792 1.5× 245 1.0× 68 0.4× 517 4.0× 225 1.8× 38 1.2k
Stephen S. Grubbs United States 10 354 0.7× 45 0.2× 71 0.4× 110 0.8× 108 0.9× 30 538
S. Rocca Rossétti Italy 12 206 0.4× 99 0.4× 186 1.1× 449 3.5× 48 0.4× 26 677
J.M. Abascal Junquera Spain 14 249 0.5× 132 0.6× 37 0.2× 503 3.9× 86 0.7× 73 760
J.L. Chin Canada 6 751 1.4× 131 0.6× 78 0.5× 583 4.5× 384 3.1× 8 966
R. Pellerito Italy 13 94 0.2× 106 0.5× 50 0.3× 45 0.3× 86 0.7× 31 556
Karin Olson United States 15 262 0.5× 71 0.3× 49 0.3× 384 3.0× 73 0.6× 34 620
Frank M. Senecal United States 7 626 1.2× 406 1.7× 47 0.3× 94 0.7× 109 0.9× 9 743
Eugene Moylan Australia 11 340 0.6× 22 0.1× 91 0.6× 111 0.9× 65 0.5× 33 552

Countries citing papers authored by Silvana Spadafora

Since Specialization
Citations

This map shows the geographic impact of Silvana Spadafora's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvana Spadafora with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvana Spadafora more than expected).

Fields of papers citing papers by Silvana Spadafora

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvana Spadafora. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvana Spadafora. The network helps show where Silvana Spadafora may publish in the future.

Co-authorship network of co-authors of Silvana Spadafora

This figure shows the co-authorship network connecting the top 25 collaborators of Silvana Spadafora. A scholar is included among the top collaborators of Silvana Spadafora based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvana Spadafora. Silvana Spadafora is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Spadafora, Silvana, et al.. (2025). Immunotherapy‐Related Gastritis in Small Cell Lung Cancer Treatment With Durvalumab—A Case Report. Cancer Reports. 8(12). e70422–e70422.
2.
Stewart, David J., Sandeep Sehdev, Vishal Navani, et al.. (2024). New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices. Current Oncology. 31(5). 2453–2480. 5 indexed citations
3.
Sehdev, Sandeep, Nigel S. B. Rawson, Marcus O. Butler, et al.. (2024). Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement. Current Oncology. 31(4). 1803–1816. 4 indexed citations
4.
Zhang, Liying, Irene Karam, Keyue Ding, et al.. (2024). Correlation of CTCAE and patient-reported breast radiation dermatitis symptom scores. Supportive Care in Cancer. 32(12). 801–801.
5.
Kaplan, Alan, David J. Stewart, Gerald Batist, et al.. (2022). Access Denied? The Unintended Consequences of Pending Drug Pricing Rules. Current Oncology. 29(4). 2504–2508.
6.
Chow, Edward Kai‐Hua, Tara Behroozian, Irene Karam, et al.. (2022). Mepitel Film for the prevention of acute radiation dermatitis in breast cancer: A randomized multi-centre open-label phase 3 trial. Journal of Clinical Oncology. 40(36_suppl). 390226–390226.
7.
Karanicolas, Paul J., Michael Ott, Muriel Brackstone, et al.. (2022). Periop-01: A randomized controlled trial of extended perioperative tinzaparin to improve disease-free survival in patients with resectable colorectal cancer.. Journal of Clinical Oncology. 40(4_suppl). 124–124. 1 indexed citations
8.
Yip, Steven, Daniel E. Meyers, Jeff Sisler, et al.. (2020). Oncology education for family medicine residents: a national needs assessment survey. BMC Medical Education. 20(1). 283–283. 9 indexed citations
9.
Conlon, Michael, et al.. (2020). The Operation of Canada’s Only Virtually Operated Radiation Oncology Service During the COVID-19 Pandemic. Advances in Radiation Oncology. 6(3). 100634–100634. 4 indexed citations
10.
Spadafora, Silvana, et al.. (2015). Update on community oncology practice in Canada: A view from the trenches. 2 indexed citations
11.
Spadafora, Silvana, et al.. (2013). Primary extranodal B-cell non-Hodgkin lymphoma mimicking an endodontic lesion: report of 2 cases.. PubMed. 79. d93–d93. 14 indexed citations
12.
Straus, Sharon E., et al.. (2010). Community based intervention to optimize osteoporosis management: randomized controlled trial. BMC Geriatrics. 10(1). 60–60. 24 indexed citations
13.
Ellis, Georgiana K., Henry G. Bone, Rowan T. Chlebowski, et al.. (2009). Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Research and Treatment. 118(1). 81–87. 74 indexed citations
14.
Chlebowski, R. T., et al.. (2009). A 24-month subgroup analysis of the effect of denosumab on bone mineral density in women with breast cancer undergoing aromatase inhibitor therapy.. Cancer Research. 69(2_Supplement). 2106–2106. 2 indexed citations
15.
Straus, SE, et al.. (2009). Community-based intervention to optimise falls risk management: a randomised controlled trial. Age and Ageing. 38(6). 724–730. 26 indexed citations
16.
Ellis, Georgiana K., Henry G. Bone, Rowan T. Chlebowski, et al.. (2008). Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer. Journal of Clinical Oncology. 26(30). 4875–4882. 342 indexed citations
17.
Straus, SE, et al.. (2008). Community-based randomised controlled trial evaluating falls and osteoporosis risk management strategies. Trials. 9(1). 62–62. 15 indexed citations
18.
Ellis, Georgiana K., Rowan T. Chlebowski, Devchand Paul, et al.. (2008). Subgroup analysis of a randomized, phase III study of the effect of denosumab in women with nonmetastatic breast cancer receiving aromatase inhibitor (AI) therapy. Journal of Clinical Oncology. 26(15_suppl). 546–546. 3 indexed citations
19.
Cutsem, Eric Van, Salvatore Siena, Yves Humblet, et al.. (2007). An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Annals of Oncology. 19(1). 92–98. 128 indexed citations
20.
Burkes, R., et al.. (2000). Single agent Gemcitabine for elderly patients with non small cell lung cancer (NSCLC): A phase II study. Lung Cancer. 29(1). 32–32. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joseph D. Kohles Breakdown of academic impact, for papers by J. Brandman Breakdown of academic impact, for papers by Stephen S. Grubbs Breakdown of academic impact, for papers by S. Rocca Rossétti Breakdown of academic impact, for papers by J.M. Abascal Junquera Breakdown of academic impact, for papers by J.L. Chin Breakdown of academic impact, for papers by R. Pellerito Breakdown of academic impact, for papers by Karin Olson Breakdown of academic impact, for papers by Frank M. Senecal Breakdown of academic impact, for papers by Eugene Moylan
Rankless by CCL
2026